Outcome

This study underscores the profound impact of hyperbaric oxygen therapy (HBOT) at 2.4 atmospheres of pressure on human microvascular endothelial cells (HMEC-1). A detailed genome-wide analysis revealed significant regulation of over 8100 genes either immediately following treatment or after a 24-hour recovery period.

Introduction

Hyperbaric Oxygen Therapy (HBOT) has gained significant attention for its various medical applications primarily for its role in promoting wound healing and tissue repair. This study investigates the impact of a single 60-minute HBOT session at 2.4 atmospheres on human microvascular endothelial cells (HMEC-1) emphasizing alterations in gene expression. The findings reveal the regulation of over 8100 genes highlighting the up-regulation of immediate early transcription factors such as FOS FOSB and JUNB as well as metallothioneins and molecular chaperones related to protein damage control.

Notably the Nrf-2 oxidative stress response pathway emerged as a significant player illustrating HBOT’s protective effects against oxidative stress. The therapy not only shielded endothelial cells from oxidative damage but also enhanced cell proliferation and endothelial tube formation. These results suggest that HBOT can improve wound-healing protocols and may provide a valuable strategy for preconditioning patients prior to major surgical procedures. This study’s insights into gene expression changes pave the way for broader clinical applications of HBOT extending its benefits to various therapeutic realms focused on vascular health and tissue repair.

Results

A single 60-minute hyperbaric oxygen treatment (HBOT) at 2.4 atmospheres significantly regulated over 8100 genes in human microvascular endothelial cells (HMEC-1). Genome-wide analysis revealed immediate changes and those persisting after a 24-hour recovery period. Specifically there was substantial up-regulation of immediate early transcription factors such as FOS FOSB and JUNB alongside metallothioneins and 20 molecular chaperone genes linked to protein damage control.

A pivotal aspect of the findings was the identification of the Nrf-2 oxidative stress response pathway as a key responder to HBOT. This pathway plays a critical role in defending cells against oxidative stress. The treatment also demonstrated superior effectiveness in protecting endothelial cells from oxidative stress and promoting cell proliferation compared to 100% oxygen at 1 atmosphere.

The study also noted enhanced endothelial tube formation on Matrigel plates post-HBOT an indicator of increased angiogenesis. These effects were more pronounced following two daily HBO treatments suggesting a cumulative benefit. The comprehensive gene expression modulation confirmed by quantitative PCR underscores HBOT’s role in provoking cytoprotective and angiogenic responses in endothelial cells.

Thus HBOT appears to instigate both immediate and sustained up-regulation of protective genes and pathways pointing to its potential for improving clinical outcomes in wound healing protocols and pre-surgical patient conditioning. This study provides a robust foundation for further exploration of HBOT’s applications expanding its therapeutic potential beyond conventional uses.

Conclusion

In conclusion this study underscores the profound impact of hyperbaric oxygen therapy (HBOT) at 2.4 atmospheres on human microvascular endothelial cells. The research revealed significant regulation of over 8100 genes highlighting the up-regulation of critical immediate early transcription factors like FOS FOSB and JUNB as well as metallothioneins and molecular chaperones associated with protein damage control. The pivotal Nrf-2 oxidative stress response pathway surfaced as a key mediator exemplifying HBOT’s ability to enhance cellular defense mechanisms against oxidative stress.

These findings indicate that HBOT not only protects endothelial cells but also promotes their proliferation and tube formation suggesting potential improvements in angiogenesis. The therapeutic implications extend to enhancing wound-healing protocols and preconditioning patients for major surgery offering a cytoprotective and reparative advantage in various medical contexts.

Future research can further explore the broader clinical applications of HBOT targeting specific pathways and gene expressions identified in this study. By refining HBOT protocols there is promising potential to enhance cardiovascular health and recovery processes thereby expanding the scope of this therapeutic intervention. This research paves the way for more targeted and effective use of HBOT in medical practice harnessing its full potential to benefit patient outcomes.